Questions & answers
Everything people ask before choosing a GLP-1 program — costs, safety, insurance and the medications themselves. Answers are sourced the same way the rankings are: from checkouts, federal databases and program policies.
Choosing a program
Start with the ranking or the full table.
Embody currently ranks first of 31 programs at 9.3 out of 10, with bmiMD (8.5) and Gala Health (7.7) close behind. The lowest verified price across the whole register is $59 a month. The right pick still depends on your state, your budget and whether you want brand-name or compounded medication — the segments under the ranking break each of those out.
Brand-name medication (Ozempic, Wegovy, Zepbound) is FDA-approved, and it is the default if your insurance covers it or you can pay the manufacturer’s direct-pay rate. Compounded semaglutide is the cash-pay route, and it is where the low monthly prices come from — legal, but not an FDA-approved product, so the pharmacy behind it is the deciding variable. That is exactly what each review checks.
Telehealth programs typically review an intake within one to three days and ship the same week. Your own physician takes longer, but is the only route to insurance-covered brand-name medication.
Yes. Request your records and dose history — a program has to provide them — then complete the new program’s intake. Month-to-month programs make this easiest; a prepaid plan trades that flexibility for the lower monthly price.
Costs & insurance
The full picture is on the cheapest programs.
It depends entirely on the route: what your insurance covers, the manufacturer’s direct-pay rate, the pharmacy list price, or a cash-pay telehealth program — where the lowest price we have verified is $59 a month. The cost page puts the public acquisition cost beside each one, so a quoted price has something to stand against.
The advertised rate is usually a prepaid or first-month rate. Month-to-month rates run higher, and some programs price by dose. We record both numbers with the date and the page they were read from, so a price you cannot reach at the checkout shows up as what it is.
Most cash-pay programs are, because the medication is prescribed. Confirm with your plan administrator first — some require a letter of medical necessity.
A few bill insurance; most are cash-pay by design, because coverage for weight management is patchy. If your plan covers brand-name GLP-1s, that usually beats any cash price, so check that first.
Safety & legitimacy
Every program’s record is in its review.
It is legal, and a licensed pharmacy can prepare it safely, but it is not an FDA-approved product. Safety rests on the pharmacy: licensure, sterile practice and testing. The register tracks the public record for each one, and an open FDA warning letter removes a program from every recommendation on this site.
Four fast tests. A prescription is required. The pharmacy is named and licensed in the United States. The price is plausible against what a pharmacy pays to acquire the drug, which the cost page publishes. And there are no open FDA letters against it.
No prescription required, “research use only” labeling, a price far below every verified program in the register, no named pharmacy, and payment by wire or crypto. Any one of them is disqualifying on its own.
Ratings and written verdicts are editorial judgements published by glp1watchdog.com and carried here with that attribution. They are not computed from the federal data here; the methodology page explains how each one is carried across. The rating then sets the order of the 31 programs and the verified monthly price breaks the tie, and an open critical safety flag or an open FDA warning letter bars a program from every recommendation, whatever it scores.
The medications
Talk to a clinician before acting on any of this — every program in our ranking prescribes through licensed clinicians.
Both are injectable GLP-1 receptor agonists. Semaglutide (Ozempic, Wegovy) targets GLP-1 alone; tirzepatide (Mounjaro, Zepbound) adds GIP activity and showed greater average weight loss in head-to-head trials. Tirzepatide usually costs more. Which one suits you is a clinical question.
Nausea, constipation and fatigue are the frequent ones, usually strongest while the dose is going up. Serious risks such as pancreatitis and gallbladder disease are rarer, and are why intake review and clinician follow-up matter. Report severe symptoms to your prescriber immediately.
Appetite returns, and studies show most patients regain a substantial share of the lost weight within a year without continued therapy or lifestyle change. Plan the off-ramp with your clinician before you start, not after.
The trials behind the headline numbers all paired medication with lifestyle support. The medication reduces appetite; it does not build habits. Programs that include coaching exist for exactly this.
About this site
The long version is on the about page and in the methodology.
The glp1.health editorial team. Every review, article and data page is published under the glp1.health name, and the about page says how the team works. No licensed clinician reviews these pages yet, and the site says so on every one: a page with no reviewer byline makes no clinical claim. What it publishes is cost and access data, with the source of every figure named.
Four federal sources. The CMS National Average Drug Acquisition Cost survey for what a pharmacy pays to buy each product — 1,381 price rows across 13 medications. CMS Medicare Part D for 199,389 clinician-drug records. CMS State Drug Utilization for what Medicaid paid by state. The FDA NDC directory and the FDA enforcement records for pack sizes, warning letters and 503B facilities. Program prices are not federal data: each one is read from the program's own site and recorded with the date and the page it was read from.
We list only programs we have a partner link with, and those links pay a commission when a reader signs up. When a program’s partner link ends, we remove its pages. You pay the same price either way, every paid link is marked as sponsored, and the affiliate disclosure lists where they appear. Commission buys no rating and no ranking position.
Yes. It published as glp1foryou.com until 2026, then moved to glp1.health. Same owner, same sources, same method — only the domain changed.
